SOUTH SAN FRANCISCO - Aligos Therapeutics, Inc. (NASDAQ:ALGS), a company specializing in therapies for liver and viral diseases with a current market capitalization of $96.58 million, announced today ...

Aligos Therapeutics (ALGS) has entered into a securities purchase agreement for a private placement that is expected to result in gross ...

"With committed financing in place and these necessary regulatory approvals secured, QXO is prepared to complete this ...

Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE ...

Check the time stamp on this data. Updated AI-Generated Signals for Aligos Therapeutics Inc. (ALGS) available here: ALGS.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Aligos Therapeutics Inc. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment ...

Check the time stamp on this data. Updated AI-Generated Signals for Aligos Therapeutics Inc. (ALGS) available here: ALGS.

ALGS stock soars to 52-week high, hits $44.5 amid robust gains Aligos Therapeutics Inc. (ALGS) stock has reached a new 52-week high, touching $44.5 as the company rides a wave of positive momentum.